Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
Rhea-AI Summary
Mineralys Therapeutics (NASDAQ: MLYS) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Monday, November 10, 2025.
The company will host a conference call and live webcast on Monday, November 10, 2025 at 4:30 p.m. ET. Domestic dial-in is 1-877-704-4453, international dial-in is 1-201-389-0920, and the conference ID is 13756051. The webcast will be available on the company’s Investor Relations "News & Events" page.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, MLYS declined 4.14%, reflecting a moderate negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $126M from the company's valuation, bringing the market cap to $2.92B at that time.
Data tracked by StockTitan Argus on the day of publication.
RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2025, after the financial markets close on Monday, November 10, 2025.
| Monday, November 10th @ 4:30 p.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Conference ID: | 13756051 |
| Webcast: | Webcast Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) report Q3 2025 results?
What time is the Mineralys Therapeutics (MLYS) Q3 2025 conference call?
How do I join the Mineralys Therapeutics (MLYS) conference call on November 10, 2025?
Where can investors find the Mineralys Therapeutics (MLYS) webcast for the Q3 2025 call?
What period do the Q3 2025 results for Mineralys Therapeutics (MLYS) cover?
